AKI Epidemiology and Outcomes: A Retrospective Cohort Study from the Prenephrology Era
Table 3
Distribution of epidemiological and morbidity-associated characteristics in surviving versus nonsurviving subjects and in those with versus without recovery of kidney function (renal recovery).
Risk factor
Survival (yes or yes vs. no)
value
Renal recovery (yes or yes vs. no)
value
Gender (%)
f: 46.7; m: 53.3
0.29
f: 47.8; m: 5.2
0.54
Age (mean years ± SEM)
72.8 ± 0.6 vs. 74.9 ± 1.1
0.12
69.3 ± 1.2 vs. 74.6 ± 0.6
<0.001
DOS (mean days ± SEM)
16 ± 0.8 vs. 10.6 ± 0.9
<0.001
20.6 ± 2.2 vs. 12.8 ± 0.5
<0.001
Preexisting CKD (%)
62.6 vs. 58.7
0.44
23.2 vs. 73.5
<0.001
AKI onset (outpatient vs. in-hospital, %)
o: 66.7 vs. i: 53.7
0.01
o: 69.4 vs. i: 61.4
0.13
Dialysis due to AKI (%)
4.3 vs. 9.4
0.03
0.9 vs. 6.9
0.01
Creatinine initially (micromole/L ± SEM)
239 ± 11.2 vs. 236 ± 14.9
0.88
180 ± 12.7 vs. 256 ± 11.1
<0.001
CRP initially (mg/L ± SEM)
86.7 ± 5.6 vs. 108 ± 10.5
0.5
100 ± 10 vs. 89 ± 5.7
0.35
Vasopressor (%)
23 vs. 52.3
<0.001
30.4 vs. 31.1
0.88
Invasive ventilation (%)
20.5 vs. 46.1
<0.001
30.4 vs. 26.4
0.41
Arterial hypertension (%)
89.5 vs. 89.1
0.88
84.1 vs. 91
0.03
Coronary artery disease (%)
31.4 vs. 39.8
0.08
23 vs. 37
0.006
Chronic heart failure (%)
40.8 vs. 43
0.66
27.4 vs. 45.7
<0.001
Diabetes mellitus (%)
34.8 vs. 43.8
0.07
28.6 vs. 39.7
0.03
Obesity (%)
16 vs. 15.6
0.86
15.9 vs. 14.9
0.8
Neoplasia (%)
29 vs. 31.2
0.64
30 vs. 29.6
0.92
The values in bold represent statistically significant results.
